Want to see HK:1873 full AI Analyst Report?
1873 Stock Chart & Stats
HK$1.76
-HK$0.01(-1.20%)
At close: 4:00 PM EST
HK$1.76
-HK$0.01(-1.20%)
Day’s Range― - ―
52-Week RangeHK$1.04 - HK$3.27
Previous CloseN/A
Volume129.00K
Average Volume (3M)10.31M
Market Cap
HK$2.70B
Enterprise ValueHK$2.31B
Total Cash (Recent Filing)HK$1.13B
Total Debt (Recent Filing)HK$1.33B
Price to Earnings (P/E)11.3
Beta2.08
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding2,093,553,500
10 Day Avg. Volume10,852,121
30 Day Avg. Volume10,305,290
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)0.99
Price to Sales (P/S)2.28
P/FCF Ratio44.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.13B
Bulls Say, Bears Say
Bulls Say
Business Model DiversificationViva’s dual model combines stable, contract-based CRO service revenue with an innovation/venture arm that can generate outsized, non-linear returns via program monetizations. This mix supports recurring cashflow from services while preserving long-term upside from incubated assets.
Margin And Profitability StabilityConsistent mid-30% gross margins and low-teens operating margins, plus a return to net profits, indicate durable unit economics for discovery-stage R&D services. Stable margins help sustain earnings through cycles and fund ongoing investment in capabilities and platform expansion.
Improving Leverage ProfileMaterial reduction in leverage improves financial flexibility and lowers refinancing risk, allowing the company to fund R&D, service capacity, and venture investments without excessive credit strain. A stronger balance sheet supports long-term partnerships and continuity of operations.
Bears Say
Persistent Revenue DeclineSustained top-line contraction weakens the scalability of fixed-cost leverage and puts pressure on long-term margin expansion. Continued revenue declines reduce pricing power and client footprint, making it harder to convert positive margins into durable earnings growth without a credible revenue-recovery plan.
Weak Cash-flow MomentumA sharp ~59% drop in free cash flow and weakening operating cashflow reduce internal funding for R&D and venture investments, and increase reliance on external financing. Even with positive FCF in 2024–2025, the volatility undermines confidence in consistent cash generation.
Profitability VolatilityEarnings swings across cycles make planning and capital allocation challenging, and mean the balance sheet depends on sustained profitability to keep credit metrics comfortable. Volatility heightens the risk that a future downturn could force strategic trade-offs or external capital needs.
Viva Biotech Holdings News
1873 FAQ
What was Viva Biotech Holdings’s price range in the past 12 months?
Viva Biotech Holdings lowest stock price was HK$1.04 and its highest was HK$3.27 in the past 12 months.
What is Viva Biotech Holdings’s market cap?
Viva Biotech Holdings’s market cap is HK$2.70B.
When is Viva Biotech Holdings’s upcoming earnings report date?
Viva Biotech Holdings’s upcoming earnings report date is Aug 31, 2026 which is in 27 days.
How were Viva Biotech Holdings’s earnings last quarter?
Viva Biotech Holdings released its earnings results on Mar 30, 2026. The company reported HK$0.051 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.051.
Is Viva Biotech Holdings overvalued?
According to Wall Street analysts Viva Biotech Holdings’s price is currently Overvalued.
Does Viva Biotech Holdings pay dividends?
Viva Biotech Holdings pays a Notavailable dividend of HK$0.01 which represents an annual dividend yield of N/A. See more information on Viva Biotech Holdings dividends here
What is Viva Biotech Holdings’s EPS estimate?
Viva Biotech Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viva Biotech Holdings have?
Viva Biotech Holdings has 2,093,553,500 shares outstanding.
What happened to Viva Biotech Holdings’s price movement after its last earnings report?
Viva Biotech Holdings reported an EPS of HK$0.051 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.785%.
Which hedge fund is a major shareholder of Viva Biotech Holdings?
Currently, no hedge funds are holding shares in HK:1873
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viva Biotech Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
Viva Biotech Holdings
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―